钠-葡萄糖共转运蛋白抑制剂在心脏-肾脏代谢综合征中的发展和现状。
Development and Current Role of Sodium Glucose Cotransporter Inhibition in Cardiorenal Metabolic Syndrome.
机构信息
Clinical Pharmacist-Diabetes Transition, Department of Nursing Administration, Spartanburg Regional Healthcare System, Spartanburg, SC.
出版信息
J Cardiovasc Pharmacol. 2022 May 1;79(5):593-604. doi: 10.1097/FJC.0000000000001248.
Sodium-glucose cotransporter-2 inhibitors were approved as adjunct therapy for the management of type 2 diabetes and have become a high-level recommendation for this population with cardiorenal metabolic syndrome. In addition, evidence continues to grow supporting this class of medications for people with heart failure and chronic kidney disease, regardless of diabetes status. This narrative review summarizes the sodium-glucose cotransporter inhibitors for cardiorenal metabolic syndrome.
钠-葡萄糖共转运蛋白 2 抑制剂被批准作为 2 型糖尿病管理的辅助治疗方法，已成为伴有心肾代谢综合征这一人群的高级别推荐。此外，越来越多的证据支持该类药物用于心力衰竭和慢性肾脏病患者，无论其糖尿病状况如何。本综述性叙述总结了钠-葡萄糖共转运蛋白 2 抑制剂在心肾代谢综合征中的应用。
Zotero 插件